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Subtitle: The force required to expel a drop differs between Prostaglandin 
monotherapy dropper designs and some exceeded the maximum force that could be 
comfortably applied by around half the population, which may affect compliance and 
efficacy. 
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ABSTRACT 
Aim: To determine the force needed to extract a drop from a range of current 
prostaglandin monotherapy eye droppers and how this related to the comfortable 
and maximum pressure subjects could exert. 
Methods: The comfortable and maximum pressure subjects could apply to an 
eye dropper constructed around a set of cantilevered pressure sensors and mounted 
above their eye was assessed in 102 subjects (mean 51.2±18.7 years), repeated 
3 times.  A load cell amplifier, mounted on a stepper motor controlled linear slide, 
was constructed and calibrated to test the force required to extract the first 3 drops 
from 13 multi-dose or uni-dose latanoprost medication eye droppers. 
Results:  The pressure that could be exerted on a dropper comfortably 
(25.9±17.7 newtons, range 1.2 to 87.4) could be exceeded with effort (to 64.8±27.1 
newtons, range 19.9 to 157.8; F=19.045, p<0.001), but did not differ between 
repeats (F=0.609, p=0.545). Comfortable and maximum pressure exerted were 
correlated (r=0.618, p<0.001), neither were influenced strongly by age (r=0.138, 
p=0.168; r=-0.118, p=0237 respectively), but were lower in females than males 
(F=12.757, p=0.001). The force required to expel a drop differed between dropper 
designs (F=22.528, p<0.001), ranging from 6.4 to 23.4 newtons. The force needed to 
exert successive drops increased (F=36.373, p<0.001) and storing droppers in the 
fridge further increased the force required (F=7.987, p=0.009).  
Conclusions: Prostaglandin monotherapy droppers for glaucoma treatment 
vary in their resistance to extract a drop and with some a drop could not be 
comfortably achieved by half the population, which may affect compliance and 
efficacy. 
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INTRODUCTION 
About 11% of patients report difficulty in administering their glaucoma medication.[1] 
Approximately ~17% rely on others for the administration of drops due to inadequate 
vision and trouble with manual dexterity.[2] If it is hard to expel the required dose 
from a medication dropper, compliance can be affected.[3] Ease of use is also 
related to a patient’s satisfaction, resistance to using their medication, their 
acceptance of their illness [4] and their health related quality of life.[5] The US patent 
for Xalatan expired in March 2011 and since then generic formulations of latanoprost 
have been available. While it is acknowledged these are cost effective,[6] FDA 
regulations do not dictate dropper design or rigidity and hence some patients may 
find these generics difficult to use, affecting compliance and therefore treatment 
efficacy.[7] 
  
Hence this study determined the force needed to extract a drop from a range of 
current prostaglandin monotherapy medication eye dropper designs and related this 
to the comfortable and maximum squeeze pressure a wide age range of healthy 
subjects could exert. 
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METHODS 
One-hundred and two consecutive healthy subjects attending a high street optometry 
practice (51% female) aged 19-88 years (mean 51.2 ± 18.7 years) were recruited. 
The comfortable and maximum pressure they could apply between their thumb and 
index finger to an eye dropper constructed around a set of cantilevered pressure 
sensors (Richmond Industries, UK; Figure 1) and mounted above their eye was 
assessed, repeated 3 times. Those with known arthritis affecting their fingers, 
Parkinson’s disease or diabetes were excluded from the study. An explanation and 
demonstration was provided and subjects were asked to apply the “maximum 
pressure they could apply comfortably” followed by the “maximum pressure they 
could apply with effort” to the simulated dropper for 3 seconds before releasing. The 
subjects gave informed consent and the research, which conformed to the tenets of 
the declaration of Helsinki, was approved by the Aston University Research Ethics 
Committee.   
 
In a separate aspect to the study, a load cell amplifier (Richmond Industries, UK) 
mounted on a stepper motor controlled linear slide (Trinamic GmbH, Germany; 
Geckodrive Inc., USA) was constructed (Figure 1). This device was used to 
mechanically test the force required to extract the first 3 drops from 13 multi-dose 
(MD) or uni-dose (UD) latanoprost medication eye dropper designs (Table 1), 
repeated on three droppers of each design from different production lots. In addition 
the force required to extract the first 3 drops from an additional dropper of each 
design, which had been refrigerated at 6ºC for 24 hours, was assessed. The load 
cell was calibrated against known masses and calibration was maintained 
throughout the testing period.  
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The volume of the droplets was quantified with a custom high speed photography 
system that imaged the droplet in freefall against a backlit light emitting diode (LED) 
panel producing a sharp outline of the droplet’s edge (Figure 1). The camera used 
was an IDS UI-1221LE (Imaging Development Systems GmbHIDS, Obersulm, 
Germany) with a custom optical set up, approximating a 16mm focal length. Sensor 
binning (combining charge from adjacent pixels) was used to increase the frame rate 
of the capture system, allowing 280 frames per second (fps) to be achieved with 80 
pixels across the droplet diameter. Calibration was undertaken determining 
magnification at the image plane by imaging known size objects, producing a 
suitable scaling factor for each dropper nozzle. Software was written in LabVIEW 
(Labview 2013, National Instruments, Austin, Texas, USA) to select the droplet 
immediately after release into free-fall on the captured video and to export images 
for post processing. A semi-automated circle fitting algorithm, developed in ImageJ 
(U. S. National Institutes of Health, Bethesda, Maryland, USA), was applied to the 
edge of the droplet in free-fall to determine its diameter. Calculations were performed 
assuming the droplet in free-fall held a spherical shape due to surface tension, which 
allowed extrapolation of the measured diameter to determine its volume. 
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RESULTS   
The pressure that could be exerted on a dropper when subjects’ applied the 
maximum squeeze they could employ comfortably (25.9 ± 17.7 newtons, range 1.2 
to 87.4) could be exceeded with effort (to 64.8 ± 27.1 newtons, range 19.9 to 157.8; 
F = 19.045, p < 0.001), but did not differ between repeats (ANOVA F = 0.609, p = 
0.545; Figure 2). The comfortable and maximum pressure that subjects’ could exert 
on a dropper bottle were correlated (r = 0.618, p < 0.001), but neither were 
influenced strongly by age (r = 0.138, p = 0.168; r = -0.118, p = 0237 respectively). 
Both the comfortable and maximum pressure that subjects could exert on a dropper 
bottle were lower in females than males (18.5 ± 10.4 vs 33.6 ± 20.4 newtons and 
47.7 ± 13.6 vs 82.5 ± 26.3 newtons; F = 12.757, p = 0.001).  
 
The force required to mechanically expel a drop differed between dropper designs (F 
= 22.528, p < 0.001), with the force ranging from 6.4 to 23.4 newtons (Table 1; 
Figure 3). In general, the force needed to expel successive drops increased (F = 
36.373, p < 0.001) and storing the droppers in the fridge further increase the force 
required to expel a drop (15.75 ± 6.43 vs 14.72 ± 7.06 newtons: F = 7.987, p = 
0.009; Figure 3). Expelled drop size is reported in table 1 and was significantly 
correlated to the force required to expel a drop (r = 0.526, p < 0.001). 
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Figure 2: The force that could be exerted comfortably and with maximum 
exertion with subject’s age. N = 102. 
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Figure 3: Pressure required to expel a drop of prostaglandin monotherapy 
medications. Error bars = 1 S.D. * = p < 0.05 and NS = not significantly 
different compared to Xalatan. 
 
 
10 
 
Product  Company 
Unidose/ 
Multidose 
Size 
(ml) 
Dose 
(mg/ml) 
Drop Size 
(µl) 
Force 
(N)  XalaTAN  Travatan  Lumigan  Lumigan  Lumigan  Saflutan  G1  G2  G3  G4  G5  G6 
Monoprost  Thea  UD  0.2  50.00  0.021±0.010 10.5±2.5 0.124 0.001 1.000 0.034 1.000 0.882 0.578 1.000 1.000 0.260 1.000 0.000 
XalaTAN  Pfizer  MD  2.5  50.00  0.033±0.012 6.4±0.9 0.000 1.000 0.000 0.003 0.000 0.000 1.000 0.172 0.000 0.002 0.000 
Travatan  Alcon  MD  2.5  40.00  0.043±0.013 16.8±2.1 0.000 1.000 0.050 0.551 1.000 0.001 0.005 1.000 0.019 0.001 
Lumigan  Allergan  UD  0.4  0.30  0.027±0.010 9.1±2.5  0.001 0.763 0.023 0.024 1.000 1.000 0.016 0.801 0.000 
Lumigan  Allergan  MD  3.0  0.10  0.029±0.010 15.2±3.1  1.000 1.000 1.000 0.015 0.100 1.000 0.580 0.000 
Lumigan  Allergan  MD  3.0  0.30  0.032±0.010 12.2±1.3  1.000 1.000 1.000 1.000 1.000 1.000 0.000 
Saflutan  MSD  UD  0.3  15.00  0.020±0.009 13.5±3.6  1.000 0.329 1.000 1.000 1.000 0.000 
Latanoprost‐G1  Tubilux  MD  2.5  50.00  0.032±0.011 14.1±2.1  0.229 1.000 1.000 1.000 0.000 
Latanoprost‐G2  TEVA  MD  2.5  50.00  0.035±0.011 9.7±1.5  1.000 0.111 1.000 0.000 
Latanoprost‐G3  actavis  MD  2.5  50.00  0.036±0.011 10.7±1.1  0.506 1.000 0.000 
Latanoprost‐G4  Pfizer  MD  2.5  50.00  0.035±0.011 15.1±1.3   1.000 0.000 
Latanoprost‐G5  Sandoz  MD  2.5  50.00  0.030±0.010 12.0±2.4    0.000 
Latanoprost‐G6  Beacon  MD  2.5  50.00  0.040±0.012 23.4±2.4 
Table 1: Products tested, the drop size (± 1S.D.), mean force required to compress (± 1S.D.), and the significance between 
them. G1-6 = generics 
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DISCUSSION 
This study aimed to determine the force needed to expel a drop from a range of 
current prostaglandin monotherapy medication eye droppers and how this related to 
the comfortable and maximum pressure subjects’ could exert. The maximum 
pressure that could be exerted on a dropper without exceeding the subject’s 
individual comfort threshold ranged over 70 fold between individuals and was about 
40% lower than the pressure that could be exceeded with effort. Interestingly neither 
the pressure that could be exerted comfortably or with maximum effort on a dropper 
bottle was influenced strongly by age, but both were about 1.8x lower in females. 
The values of maximum force recorded in this study relate well to pinch grip (typically 
recorded in kilograms where 10 newtons = 1 Kg), where the average pinch grip is 
around 7-9Kg in males and 5-6Kg in females. Pinch grip doesn’t significantly decline 
until after the age of 70 to 80 years, and has a peak in the mid-30s.[8, 9]. Despite the 
lack of correlation of squeeze pressure that could be applied with age, this reported 
profile appears to fit with the data collected in this study (Figure 2).     
 
The force required to expel a drop from a prostaglandin monotherapy for glaucoma 
varied greatly with dropper design, with the force required between droppers varying 
3.7 fold. A similar range of pressure required to expel a drop with various glaucoma 
and other topical ophthalmic medication bottles has been found previously.[10] 
Droppers that required the highest mechanical pressures to expel a drop in this 
study would cause over 50 per cent of subjects discomfort in their attempt to do so 
(i.e. was more than their objectively measured maximum comfortably exerted 
squeeze pressure), which is likely to affect compliance and hence treatment 
efficacy.[3] This is despite the range of ages of subjects tested encompassing those 
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below the age of 40 when glaucoma is less common, although this age range makes 
the results applicable to other conditions requiring topical ocular medication such as 
dry eye. Bottles with low pressure required to expel a drop may run out quickly due 
to over expression and the inability to easily expel individual drops could lead to 
overdosing and epiphora. The drop size was in the range of that reported previously 
[11], although it varied by over 2 fold between dropper designs. The drop size was 
correlated to the force required to expel a drop, suggesting that dropper design 
affects dose through the pressure required to expel a drop.  
 
In general, the force needed to expel successive drops from all dropper designs 
increased, and further so with refrigeration. No previous studies appear to have 
examined the effect of storing drops in the fridge, as recommended, and the 
previous study on drop size only examined the first drop.[10] 
 
In conclusion, prostaglandin monotherapy medication droppers vary in their 
resistance to extract a drop and a drop could not be comfortably achieved by all 
subjects, which may affect compliance and efficacy. 
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